RxDoctor Payments Data

Benjamin Wiele, MD

Cardiovascular Disease · Saint Louis, MONPI 1164777694

Payments from drug & device makers

$1,522in general payments, 2019–2025

Across 59 payments — averaging $25.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$249
  • Boston Scientific$173
  • Heartflow, Inc.$172
  • Actelion Pharmaceuticals US, Inc.$148
  • Novartis$122
  • Amgen$95
  • plus $562 from 14 others

What the payments were for

  • Food & beverage$1,522100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,522 in reported general payments places this provider in the 40th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$164,797
Medicare patients
1,972
Services billed
3,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban673$757,855
XareltoRivaroxaban73$97,047
Repatha SureclickEvolocumab129$94,651
EntrestoSacubitril/Valsartan58$76,402
JardianceEmpagliflozin36$40,634
FarxigaDapagliflozin Propanediol34$40,333
Praluent PenAlirocumab35$20,533
VascepaIcosapent Ethyl22$15,693
Atorvastatin Calcium887$6,733
BrilintaTicagrelor11$6,707
Metoprolol Succinate539$5,842
Diltiazem 24hr Er (Cd)Diltiazem Hcl81$4,065
Rosuvastatin Calcium277$3,523
Carvedilol476$3,331
Dabigatran EtexilateDabigatran Etexilate Mesylate16$3,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$89$757,855673 claims
Johnson & JohnsonXarelto$19$97,04773 claims
NovartisEntresto$122$76,40258 claims
AstraZenecaFarxiga, Brilinta$67$47,04045 claims
Boehringer IngelheimJardiance$78$40,63436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →